QTEX QTREX Quantum Ltd. Annual reports only
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1837493 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-19.6%
TTM EPS YoY25.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin0.7%
Operating margin-4,713.8%
Net margin-4,574.4%
FCF margin-3,447.8%
EBITDA margin-4,661.9%
Returns
ROE-397.9%
ROA-197.2%
ROIC (approx.)—
Asset turnover0.04x
Leverage & solvency
Liabilities / assets56.5%
Debt / equity0.00x
Current ratio1.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-50.1%
Payout ratio—
Capex / revenue35.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $289,000 | $0 |
| Cost of revenue | $287,000 | $0 |
| Gross profit | $2,000 | $0 |
| R&D expense | $7.50M | $6.32M |
| SG&A expense | $5.53M | $4.18M |
| Operating income | -$13.62M | -$11.27M |
| Pretax income | -$13.22M | -$11.05M |
| Income tax | $0 | $0 |
| Net income | -$13.22M | -$11.05M |
| EBITDA | -$13.47M | -$11.10M |
| EPS (basic) | -0.45 | -0.60 |
| EPS (diluted) | -0.45 | -0.60 |
| Weighted avg. shares (diluted) | 29.62M | 18.52M |
| Balance sheet | ||
| Cash & equivalents | $3.16M | $5.11M |
| Short-term investments | — | $700,000 |
| Inventory | $735,000 | $444,000 |
| Current assets | $4.41M | $6.81M |
| PP&E, net | $452,000 | $499,000 |
| Total assets | $5.34M | $8.07M |
| Current liabilities | $2.82M | $3.37M |
| Total liabilities | $3.02M | $3.75M |
| Shareholders' equity | $2.32M | $4.32M |
| Shares outstanding | 35.95M | 24.25M |
| Cash flow statement | ||
| Operating cash flow | -$9.86M | -$9.37M |
| Capital expenditure | $103,000 | $164,000 |
| Free cash flow | -$9.96M | -$9.54M |
| Investing cash flow | $565,000 | $1.49M |
| Financing cash flow | $7.33M | $7.90M |
| Depreciation & amortization | $150,000 | $171,000 |
| Stock-based compensation | $3.58M | $1.89M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.